JP7062673B2 - 前立腺がんの治療 - Google Patents

前立腺がんの治療 Download PDF

Info

Publication number
JP7062673B2
JP7062673B2 JP2019538720A JP2019538720A JP7062673B2 JP 7062673 B2 JP7062673 B2 JP 7062673B2 JP 2019538720 A JP2019538720 A JP 2019538720A JP 2019538720 A JP2019538720 A JP 2019538720A JP 7062673 B2 JP7062673 B2 JP 7062673B2
Authority
JP
Japan
Prior art keywords
administration
oral
weeks
present disclosure
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019538720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529574A5 (enExample
JP2019529574A (ja
Inventor
ラジャセクアール、ヴィジェイクマール、レディ
マーク ジョンソン、ブレンダン
ビー． マクリーン、デイヴィッド
シーリ、リン
エヌ． マッド、ジュニア、ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7062673(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2019529574A publication Critical patent/JP2019529574A/ja
Publication of JP2019529574A5 publication Critical patent/JP2019529574A5/ja
Application granted granted Critical
Publication of JP7062673B2 publication Critical patent/JP7062673B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2019538720A 2016-09-30 2017-09-29 前立腺がんの治療 Active JP7062673B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662402150P 2016-09-30 2016-09-30
US201662402004P 2016-09-30 2016-09-30
US62/402,004 2016-09-30
US62/402,150 2016-09-30
PCT/EP2017/074849 WO2018060463A2 (en) 2016-09-30 2017-09-29 Treatment of prostate cancer

Publications (3)

Publication Number Publication Date
JP2019529574A JP2019529574A (ja) 2019-10-17
JP2019529574A5 JP2019529574A5 (enExample) 2020-11-12
JP7062673B2 true JP7062673B2 (ja) 2022-05-06

Family

ID=60915459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019538720A Active JP7062673B2 (ja) 2016-09-30 2017-09-29 前立腺がんの治療

Country Status (21)

Country Link
US (8) US10449191B2 (enExample)
EP (2) EP4520398A3 (enExample)
JP (1) JP7062673B2 (enExample)
CN (1) CN110248661A (enExample)
AU (2) AU2017334035B2 (enExample)
BR (1) BR112019006228A2 (enExample)
CA (1) CA3038875A1 (enExample)
DK (1) DK3518932T3 (enExample)
ES (1) ES3002857T3 (enExample)
FI (1) FI3518932T3 (enExample)
HR (1) HRP20241740T1 (enExample)
HU (1) HUE070578T2 (enExample)
IL (3) IL300071A (enExample)
LT (1) LT3518932T (enExample)
MA (1) MA46361A (enExample)
MX (2) MX2019003733A (enExample)
NZ (1) NZ752918A (enExample)
PL (1) PL3518932T3 (enExample)
PT (1) PT3518932T (enExample)
SI (1) SI3518932T1 (enExample)
WO (1) WO2018060463A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202200255T1 (it) 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea
SI3518932T1 (sl) 2016-09-30 2025-03-31 Takeda Pharmaceutical Company Limited Zdravljenje raka prostate
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
WO2021069700A1 (en) * 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
US20230384316A1 (en) * 2020-10-20 2023-11-30 Baylor College Of Medicine Multiplex metabolic markers in plasma for early detection of african american prostate cancer
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
WO2023152611A1 (en) * 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016136849A1 (ja) 2015-02-26 2016-09-01 武田薬品工業株式会社 固形製剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710637B1 (fr) 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
US6849738B2 (en) 2000-02-29 2005-02-01 Takeda Chemical Industries, Ltd. Processes for the production of thienopyrimidine derivatives
WO2002024230A1 (en) 2000-09-22 2002-03-28 Takeda Chemical Industries, Ltd. Solid preparations
WO2003057689A1 (en) 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
EP1479684A4 (en) 2002-01-30 2006-01-04 Takeda Pharmaceutical THIENOPYRIMIDINES, METHODS OF MAKING AND USING SAME
CN1326569C (zh) 2002-02-26 2007-07-18 阿斯特拉曾尼卡有限公司 含有水溶性纤维素衍生物的iressa药物制剂
CN101153042A (zh) 2003-01-29 2008-04-02 武田药品工业株式会社 噻吩并嘧啶化合物及其用途
EP1646389B1 (en) 2003-07-07 2008-09-10 Neurocrine Biosciences, Inc. Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
KR20080041662A (ko) 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 조기 배란 예방제
MX2009010828A (es) 2007-04-06 2009-10-29 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de gonadotropina y metodos relacionados con los mismos.
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
US20110172249A1 (en) 2008-09-03 2011-07-14 Takeda Pharmaceutical Company Limted Method for improving absorbability of preparation, and preparation having improved absorbability
SMT202200255T1 (it) 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea
AU2015308987B2 (en) 2014-08-26 2021-02-18 Kaass Discovery As Methods, agents and compositions for treatment of inflammatory conditions
WO2017040841A1 (en) 2015-09-01 2017-03-09 Abbvie Inc. Methods of administering elagolix
US20180044977A1 (en) 2016-08-12 2018-02-15 Raynor Mfg. Co. Rolling door construction for controlling air leakage
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
SI3518932T1 (sl) 2016-09-30 2025-03-31 Takeda Pharmaceutical Company Limited Zdravljenje raka prostate
CN115626933A (zh) 2022-10-20 2023-01-20 上海医药工业研究院有限公司 一种瑞卢戈利盐溶剂合物、其制备方法和应用
CN115504994A (zh) 2022-10-20 2022-12-23 上海医药工业研究院有限公司 一种瑞卢戈利盐的晶型、其制备方法和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016136849A1 (ja) 2015-02-26 2016-09-01 武田薬品工業株式会社 固形製剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ClinicalTrials.gov archive, NCT02083185, A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Patients With Prostate Cancer, May 6 2016， https://clinicaltrials.gov/cv2/history/NCT02083185?V 9=View#StudyPageTop［検索日：07/10/2021］
CliticalTrials.gov archive, NCT02135445, Safety and Efficacy of TAK-385 for Patients with Localized Prostate Cancer, May 6 2016， https://clinicaltrials.gov/cv2/history/NCT02135445?V 7=View#StudyPageTop ［検索日：07/10/2021]
European Journal of Pharmacology，2014年，723，pp.167-174
J Clin Endocrinol Metab，2015年，100(12)，pp.4579-4587
Journal of Medicinal Chemistry，2011年，54，pp.4998-5012

Also Published As

Publication number Publication date
HRP20241740T1 (hr) 2025-02-28
CN110248661A (zh) 2019-09-17
ES3002857T3 (en) 2025-03-07
IL265697B1 (en) 2023-03-01
FI3518932T3 (fi) 2025-02-03
PT3518932T (pt) 2025-01-16
AU2023201047B2 (en) 2025-04-03
US12336990B2 (en) 2025-06-24
AU2023201047A1 (en) 2023-03-23
US20210205303A1 (en) 2021-07-08
US20220401443A1 (en) 2022-12-22
BR112019006228A2 (pt) 2019-06-18
CA3038875A1 (en) 2018-04-05
SI3518932T1 (sl) 2025-03-31
US20250057839A1 (en) 2025-02-20
US20250332166A1 (en) 2025-10-30
US20250082632A1 (en) 2025-03-13
WO2018060463A3 (en) 2018-05-11
MX2019003733A (es) 2019-09-26
AU2017334035B2 (en) 2022-11-24
IL300071A (en) 2023-03-01
PL3518932T3 (pl) 2025-04-07
EP3518932B1 (en) 2024-11-13
IL265697B2 (en) 2023-07-01
US12629370B2 (en) 2026-05-19
AU2017334035A1 (en) 2019-05-16
HUE070578T2 (hu) 2025-06-28
US10786501B2 (en) 2020-09-29
EP4520398A3 (en) 2025-04-02
LT3518932T (lt) 2025-02-10
US20240358700A1 (en) 2024-10-31
US12097198B2 (en) 2024-09-24
NZ752918A (en) 2022-09-30
US10449191B2 (en) 2019-10-22
US11583526B2 (en) 2023-02-21
US20200129507A1 (en) 2020-04-30
US12144809B1 (en) 2024-11-19
DK3518932T3 (da) 2025-01-27
JP2019529574A (ja) 2019-10-17
US20190224196A1 (en) 2019-07-25
IL265697A (en) 2019-05-30
MA46361A (fr) 2021-03-31
WO2018060463A2 (en) 2018-04-05
MX2023001468A (es) 2023-03-03
EP4520398A2 (en) 2025-03-12
EP3518932A2 (en) 2019-08-07
IL308528A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
US12336990B2 (en) Treatment of prostate cancer
US11957684B2 (en) Treatment of heavy menstrual bleeding associated with uterine fibroids
EP4243829A1 (en) Methods of administering relugolix
AU2016262826A1 (en) Selective progesterone receptor modulator (SPRM) regimen
HK40116485A (en) Treatment of prostate cancer
EA043716B1 (ru) Лечение рака предстательной железы
HK40012835A (en) Treatment of prostate cancer
HK40012835B (en) Treatment of prostate cancer
EA041715B1 (ru) Способы лечения миомы матки и обильного менструального кровотечения
EA049363B1 (ru) Способы лечения эндометриоза и боли,связанной с эндометриозом

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220420

R150 Certificate of patent or registration of utility model

Ref document number: 7062673

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250